<DOC>
	<DOCNO>NCT02442544</DOCNO>
	<brief_summary>The gut microbiome increasingly recognize contributor disease state . In type 1 diabetes , alteration gut microbiota may link change intestinal permeability , inflammation insulin resistance . Prebiotic fiber dietary supplement alters gut microbiota could potentially improve insulin sensitivity child type 1 diabetes . This pilot study aim determine feasibility 12-week dietary intervention prebiotic fiber child type 1 diabetes . The investigator hypothesize consumption prebiotic fiber alter gut microbiota intestinal permeability , lead improved glycemic control . Prebiotic fiber potentially novel , inexpensive , low-risk treatment addition type 1 diabetes may improve glycemic control change gut microbiota , gut permeability inflammation .</brief_summary>
	<brief_title>Prebiotic Fiber Supplement T1DM Children</brief_title>
	<detailed_description>At baseline , subject complete demographic questionnaire ( age , gender , date type 1 diabetes diagnosis , current medication , medical condition , number episode severe hypoglycemia diabetic ketoacidosis since diagnosis type 1 diabetes ) anthropometric data form ( height , weight , body mass index ) . A baseline stool sample collect home . One tablespoon stool place pre-labelled sterile conical tube , place biohazard bag store home freezer ( -20°C ) . Stool sample bring laboratory ice within 3 day collection store -80°C analysis . Subjects baseline blood sample drawn HbA1c , C-peptide , inflammatory marker ( IL-6 , IFN-γ , TNF-α , IL-10 ) , GLP1 GLP2 . An intestinal permeability test perform describe . Subjects randomize receive either placebo ( maltodextrin 3.3 g orally/ day ) prebiotic fiber ( 1:1 oligofructose : inulin 8 g orally /day ) . Both approve food ingredient Canada regulate natural health product . Dr. Reimer 'no objection ' letter Health Canada previously use clinical trial ( 14 ) . Both prebiotic fiber placebo come powder form pre-measured packet . Subjects instructed mix packet 250 mL water dissolve take 15-20 minute prior even meal . For first two week , subject ask take half dose order minimize GI side effect take full dose remain 10 week . Subjects ask record diabetes related adverse reaction ( ie . severe hypoglycemia diabetic ketoacidosis ) . At end 12 week ( 3months ) , subject ask submit second stool sample repeat baseline blood test intestinal permeability test . Subjects ask return remain packet placebo prebiotic order ass compliance . A third stool sample , intestinal permeability test blood sample ( HbA1c , C-peptide , inflammatory marker ( IL-6 , IFN-γ , TNF-α , IL-10 ) , GLP1 GLP2 ) do 6 month follow . Telephone contact member research team ( research assistant PI ) occur monthly encourage compliance record adverse reaction .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>1 . Age 8 17 year old 2 . Diagnosed type 1 diabetes least one year 3 . HbA1c &lt; 10 % 6 month prior start trial 1 . Subjects another chronic medical condition could affect gut microbiota ( example : Crohn 's disease , cystic fibrosis , irritable bowel syndrome , etc . ) 2 . Subjects take medication supplement could affect gut microbiota ( example : antibiotic , probiotic , prebiotics , laxative , etc . ) 3 . Subjects positive celiac disease screen</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>